AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV

Kenji Sakamoto1, Kouhei Yoshida1,2, Yuji Tsunekawa1

  • 1Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Molecular Therapy. Advances
|August 28, 2026
PubMed

Related Concept Videos